Kezar Life Sciences Shares Are Trading Higher After the Company Announced the Voluntary Cessation in Enrollment of New Patients and Dosing of Ongoing Patients in the Phase 2b PALIZADE Clinical Trial, Pending Further Evaluation.
Kezar Life Sciences Shares Are Trading Higher After the Company Announced the Voluntary Cessation in Enrollment of New Patients and Dosing of Ongoing Patients in the Phase 2b PALIZADE Clinical Trial, Pending Further Evaluation.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.